Published in J Virol on January 01, 1988
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc Natl Acad Sci U S A (1988) 4.33
Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J (1989) 4.24
The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol (1989) 3.36
Purification of the human immunodeficiency virus type 1 enhancer and TAR binding proteins EBP-1 and UBP-1. EMBO J (1988) 2.74
Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J (1988) 2.57
NF-kappa B protein purification from bovine spleen: nucleotide stimulation and binding site specificity. Proc Natl Acad Sci U S A (1988) 2.39
Specific binding of a HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus transactivating region. Proc Natl Acad Sci U S A (1989) 2.17
Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1989) 2.14
TAR independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO J (1990) 2.00
Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J Virol (1994) 1.98
DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J Virol (1991) 1.90
Two blocks in Moloney murine leukemia virus expression in undifferentiated F9 embryonal carcinoma cells as determined by transient expression assays. J Virol (1989) 1.84
Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1991) 1.84
Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins. J Virol (1989) 1.49
Cytomegalovirus activates transcription directed by the long terminal repeat of human immunodeficiency virus type 1. J Virol (1990) 1.49
Variable role of the long terminal repeat Sp1-binding sites in human immunodeficiency virus replication in T lymphocytes. J Virol (1991) 1.45
An in vitro transcription analysis of early responses of the human immunodeficiency virus type 1 long terminal repeat to different transcriptional activators. Mol Cell Biol (1991) 1.42
Human T-cell leukemia virus types I and II exhibit different DNase I protection patterns. J Virol (1988) 1.35
Cellular factors regulate transactivation of human immunodeficiency virus type 1. J Virol (1991) 1.24
Interaction of enhancer-binding protein EBP1 (NF-kappa B) with the human immunodeficiency virus type 1 enhancer. J Virol (1990) 1.22
An antibody that binds the immunoglobulin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells. EMBO J (1993) 1.22
Repeated B motifs in the human immunodeficiency virus type I long terminal repeat enhancer region do not exhibit cooperative factor binding. Proc Natl Acad Sci U S A (1988) 1.19
Differences in the basal activity of the long terminal repeat determine different replicative capacities of two closely related human immunodeficiency virus type 1 isolates. J Virol (1990) 1.19
Lymphoid specific gene expression of the adenovirus early region 3 promoter is mediated by NF-kappa B binding motifs. EMBO J (1990) 1.12
Regulation of the visna virus long terminal repeat in macrophages involves cellular factors that bind sequences containing AP-1 sites. Mol Cell Biol (1989) 1.10
Multiple transcriptional regulatory domains in the human immunodeficiency virus type 1 long terminal repeat are involved in basal and E1A/E1B-induced promoter activity. J Virol (1989) 1.07
Probing protein-DNA interactions at the long terminal repeat of human immunodeficiency virus type 1 by in vivo footprinting. J Virol (1992) 1.03
Latent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells. J Virol (2005) 1.03
Silencing of human immunodeficiency virus long terminal repeat expression by an adenovirus E1a mutant. Proc Natl Acad Sci U S A (1990) 0.95
Induction of chronic human immunodeficiency virus infection is blocked in vitro by a methylphosphonate oligodeoxynucleoside targeted to a U3 enhancer element. J Virol (1991) 0.91
Functional interaction between transcriptional elements in the long terminal repeat of reticuloendotheliosis virus: cooperative DNA binding of promoter- and enhancer-specific factors. Mol Cell Biol (1988) 0.91
Comparison of the transcriptional activity of the long terminal repeats of simian immunodeficiency viruses SIVmac251 and SIVmac239 in T-cell lines and macrophage cell lines. J Virol (1991) 0.88
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
DNAse footprinting: a simple method for the detection of protein-DNA binding specificity. Nucleic Acids Res (1978) 30.43
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature (1984) 24.45
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A (1982) 20.55
A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes. Cell (1983) 20.32
Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell (1986) 20.08
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene. Cell (1983) 18.86
A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell (1985) 16.46
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Immunoglobulin gene transcription is activated by downstream sequence elements. Cell (1983) 15.53
Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell (1986) 15.30
Affinity purification of sequence-specific DNA binding proteins. Proc Natl Acad Sci U S A (1986) 14.92
Studies and perspectives of protein kinase C. Science (1986) 14.73
A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature (1986) 14.34
Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer (1976) 14.08
Multiple point mutations affecting the simian virus 40 enhancer. Science (1983) 13.69
Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science (1986) 12.49
Host-specific activation of transcription by tandem repeats from simian virus 40 and Moloney murine sarcoma virus. Proc Natl Acad Sci U S A (1982) 12.30
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science (1984) 11.30
The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell (1985) 11.28
Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell (1987) 11.15
A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature (1986) 8.64
Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science (1986) 8.01
Multiple sequence motifs are involved in SV40 enhancer function. EMBO J (1986) 7.76
Structure of the 5' ends of immunoglobulin genes: a novel conserved sequence. Proc Natl Acad Sci U S A (1984) 7.74
A small segment of polyoma virus DNA enhances the expression of a cloned beta-globin gene over a distance of 1400 base pairs. Nucleic Acids Res (1981) 7.57
Specific interaction between enhancer-containing molecules and cellular components. Cell (1984) 6.96
Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus. Proc Natl Acad Sci U S A (1986) 6.57
Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J (1985) 6.31
A lymphocyte-specific enhancer in the mouse immunoglobulin kappa gene. Nature (1984) 6.05
Expression and characterization of the trans-activator of HTLV-III/LAV virus. Science (1986) 5.15
AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells. Virology (1985) 4.30
Immunoglobulin heavy-chain enhancer requires one or more tissue-specific factors. Science (1985) 4.28
Stimulation of in vitro transcription from the SV40 early promoter by the enhancer involves a specific trans-acting factor. EMBO J (1984) 4.28
Interaction of cell-type-specific nuclear proteins with immunoglobulin VH promoter region sequences. Nature (1986) 4.21
A trans-acting factor is responsible for the simian virus 40 enhancer activity in vitro. Nature (1985) 4.01
Inducible binding of a factor to the c-fos enhancer. Cell (1986) 3.98
The role of the kappa enhancer and its binding factor NF-kappa B in the developmental regulation of kappa gene transcription. Cell (1987) 3.72
Cell-type specific protein binding to the enhancer of simian virus 40 in nuclear extracts. Nature (1986) 3.25
Two regulatory elements for immunoglobulin kappa light chain gene expression. Proc Natl Acad Sci U S A (1984) 2.98
Specific protein binding to the simian virus 40 enhancer in vitro. Mol Cell Biol (1986) 2.82
Duplications of a mutated simian virus 40 enhancer restore its activity. Nature (1985) 2.75
Tumor promoter, TPA, enhances replication of HTLV-III/LAV. Virology (1986) 2.51
An immunoglobulin promoter displays cell-type specificity independently of the enhancer. Nature (1985) 2.39
AIDS retrovirus (ARV-2) clone replicates in transfected human and animal fibroblasts. Science (1986) 2.34
Developmental control of a promoter-specific factor that is also regulated by the E1A gene product. Cell (1987) 2.29
The c-Ha-ras oncogene and a tumor promoter activate the polyoma virus enhancer. Cell (1987) 2.24
Cell-type preference of immunoglobulin kappa and lambda gene promoters. EMBO J (1985) 2.22
Phorbol ester induces the transcriptional stimulatory activity of the SV40 enhancer. Nature (1986) 2.22
Direct activation of resting T lymphocytes by human T-lymphotropic virus type I. Nature (1987) 1.49
Characterization of a novel HTLV-infected cell line. Blood (1984) 1.40
WHO antenatal care randomised trial for the evaluation of a new model of routine antenatal care. Lancet (2001) 6.86
Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. Soc Sci Med (1997) 6.73
Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. Health Technol Assess (2007) 6.55
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J (1989) 4.24
Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. EMBO J (1987) 4.14
West Berkshire perineal management trial. Br Med J (Clin Res Ed) (1984) 3.85
Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med (1997) 3.74
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA (1999) 3.69
Reactions of participants to the results of a randomised controlled trial: exploratory study. BMJ (1998) 2.83
Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J (1988) 2.57
The American Stop Smoking Intervention Study. Conceptual framework and evaluation design. Eval Rev (1999) 2.57
Zelen randomization: attitudes of parents participating in a neonatal clinical trial. Control Clin Trials (1999) 2.37
Epidemiological and transmissibility analysis of influenza A(H1N1)v in a southern hemisphere setting: Peru. Euro Surveill (2009) 2.35
tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes Dev (1991) 2.34
Rebound bilirubin levels in infants receiving phototherapy. J Pediatr (1998) 2.19
Specific binding of a HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus transactivating region. Proc Natl Acad Sci U S A (1989) 2.17
Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol (1999) 2.15
Patients with chronic obstructive pulmonary disease are at increased risk of death associated with urban particle air pollution: a case-crossover analysis. Am J Epidemiol (2000) 2.15
Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1989) 2.14
Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine (1995) 2.06
TAR independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO J (1990) 2.00
A randomised controlled trial of care of the perineum during second stage of normal labour. Br J Obstet Gynaecol (1998) 1.96
The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg (1998) 1.83
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia (2009) 1.80
CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha chains. J Exp Med (1998) 1.80
Labour and birth in water in England and Wales. BMJ (1995) 1.79
Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol (2007) 1.78
Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet (1983) 1.78
Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views. Health Technol Assess (2000) 1.74
Young people and healthy eating: a systematic review of research on barriers and facilitators. Health Educ Res (2005) 1.70
Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl (2002) 1.63
A discrete cis element in the human immunodeficiency virus long terminal repeat mediates synergistic trans activation by cytomegalovirus immediate-early proteins. J Virol (1991) 1.62
Trial experience and problems of parental recollection of consent. BMJ (2001) 1.60
A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci U S A (1990) 1.55
trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology (1989) 1.55
Employment in pregnancy: prevalence, maternal characteristics, perinatal outcome. Lancet (1984) 1.54
Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak. Proc Natl Acad Sci U S A (1990) 1.54
Perinatal pathology in the context of a clinical trial: attitudes of bereaved parents. Arch Dis Child Fetal Neonatal Ed (2004) 1.54
Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol (1988) 1.54
Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. J Biol Chem (2000) 1.49
Pregnant women at work. Lancet (1983) 1.48
CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology (2000) 1.46
Allergy to penicillin with good tolerance to other penicillins; study of the incidence in subjects allergic to beta-lactams. Clin Exp Allergy (1990) 1.45
Upstream regulatory regions required to stabilize binding to the TATA sequence in an adenovirus early promoter. Nucleic Acids Res (1987) 1.43
A comparative analysis of conservative versus surgical treatment of Morton's neuroma. J Am Podiatr Med Assoc (1989) 1.42
Selective immediate allergic response to penicillin V. Allergy (1996) 1.41
Breast feeding policies in practice--'no wonder they get confused'. Midwifery (1989) 1.41
Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection. Bone Marrow Transplant (1996) 1.41
Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry (1996) 1.41
Cardiac power index: staging heart failure for mechanical circulatory support. Perfusion (2012) 1.39
Perinatal pathology in the context of a clinical trial: attitudes of neonatologists and pathologists. Arch Dis Child Fetal Neonatal Ed (2004) 1.39
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol (2007) 1.39
Chronic intrahepatic cholestasis and Sicca syndrome of sarcoidosis. J Hepatol (1993) 1.39
Flavor-illness aversions: potentiation of odor by taste in rats. Behav Neural Biol (1979) 1.37
Characterization and chromosomal mapping of the gene encoding the cellular DNA binding protein HTLF. Genomics (1992) 1.36
Perinatal pathology in the context of a clinical trial: a review of the literature. Arch Dis Child Fetal Neonatal Ed (2004) 1.31
The human T-cell leukemia virus type 1 transactivator protein Tax colocalizes in unique nuclear structures with NF-kappaB proteins. J Virol (1997) 1.28
S100 protein: a marker for human malignant melanomas? Lancet (1981) 1.27
Limited sequence variation in human T-lymphotropic virus type 1 isolates from North American and African patients. Virology (1991) 1.24
Randomized study of algorithms for discontinuing tube thoracostomy drainage. J Am Coll Surg (1994) 1.23
Thiosulfate reduction, an important physiological feature shared by members of the order thermotogales. Appl Environ Microbiol (1995) 1.22
A general theory of aversion learning. Ann N Y Acad Sci (1985) 1.21
Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol Infect (1990) 1.21
Training programs for healthcare professionals in domestic violence. J Womens Health Gend Based Med (2001) 1.21
The program for in vitro fertilization at Norfolk. Fertil Steril (1982) 1.21
Prevention of nosocomial lung infection in ventilated patients: use of an antimicrobial pharyngeal nonabsorbable paste. Crit Care Med (1990) 1.19
Appendicitis as a complication of colonoscopy. Gastrointest Endosc (1995) 1.19
Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol (2006) 1.18
Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol (1991) 1.18
Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation (1995) 1.17
An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability. Eur J Neurosci (2001) 1.17
Social and ethnic inequalities in the offer and uptake of prenatal screening and diagnosis in the UK: a systematic review. Public Health (2004) 1.16
Medical students' self-assessment accuracy in communication skills. Acad Med (1997) 1.15
Typhoid fever in Santiago, Chile: a study of household contacts of pediatric patients. Am J Trop Med Hyg (1984) 1.15
The policy and practice in midwifery study: introduction and methods. Midwifery (1987) 1.14
Distribution of genital tract trauma in childbirth and related postnatal pain. Birth (1999) 1.14
Prophylaxis of Pneumocystis carinii infection in AIDS with pyrimethamine-sulfadoxine. Lancet (1984) 1.13
Flavor-illness aversions: the peculiar roles of odor and taste in memory for poison. Science (1980) 1.13
Electrocardiographic and vectorcardiographic study of interatrial conduction disturbances with left atrial retrograde activation. J Electrocardiol (1985) 1.12
Lymphoid specific gene expression of the adenovirus early region 3 promoter is mediated by NF-kappa B binding motifs. EMBO J (1990) 1.12
Mycobacterium chelonei infection of porcine heart valves. N Engl J Med (1977) 1.12
S100 protein is present in cultured human malignant melanomas. Nature (1980) 1.12
Biochemical characterization of CD1d expression in the absence of beta2-microglobulin. J Biol Chem (1999) 1.12
Solution conformation of an abasic DNA undecamer duplex d(CGCACXCACGC) x d(GCGTGTGTGCG): the unpaired thymine stacks inside the helix. Biochemistry (1997) 1.11
Improving services for disadvantaged childbearing women. Child Care Health Dev (2004) 1.09
Alterations in cytotoxic and phenotypic subsets of natural killer cells in acquired immune deficiency syndrome (AIDS). J Clin Immunol (1987) 1.08
[Industrial fluorosis. Multidisciplinary study on 43 workmen in the aluminum industry]. Schweiz Med Wochenschr Suppl (1979) 1.08